Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Combinations of a H3 antagonist and a noradrenaline reuptake inhibitor, and the therapeutical uses thereof

Combinations of a H3 antagonist and a noradrenaline reuptake inhibitor, and the therapeutical uses thereof

US Patent 12059416 · Granted Aug 13, 2024

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Dual mode 18F-labelled theranostic compounds and uses thereof2025
Benzimidazole derivatives as dual histamine H1 and histamine H4 receptor ligands2024
Benzimidazole derivatives as dual histamine H1 and histamine H4 receptor ligands2024
Benzimidazole derivatives as dual histamine H1 and histamine H4 receptor ligands2024
Cyclic peptide analogs of melanocortin and amanitin and methods of making such2024
Radiolabeled compounds targeting the prostate-specific membrane antigen2022
Cyclic peptide analogs of melanocortin and amanitin and methods of making such2022
Benzimidazole derivatives as dual histamine H1 and histamine H4 receptor ligands2022
Benzimidazole derivatives as dual histamine H1 and histamine H4 receptor ligands2022
Benzimidazole derivatives as dual histamine H1 and histamine H4 receptor ligands2022
Combinations of a H3 antagonist and a noradrenaline reuptake inhibitor, and the 2022
Combinations of a H3 antagonist and a noradrenaline reuptake inhibitor, and the 2022